Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Number of Test Conducted & Demand by Technology & Application The global c-reactive protein testing market size was $2.76 billion in 2021 and is predicted to reach $3.42 billion by 2030, representing a CAGR of 2.4% throughout the forecast period of 2021-2030. According to World Health Organization (WHO), C-reactive protein (C.R.P.) is an acute-phase protein that can be used to detect inflammation or infection early on. The protein is produced in the liver and is generally present in the blood at concentrations less than 10 mg/L. C.R.P. levels rise fast during infectious or inflammatory disease states in the first 6 to 8 hours, peaking at 350–400 mg/L after 48 hours. When the body is infected with bacteria or other cellular intruders, the liver releases C.R.P. into the bloodstream and acts as a protective shield for the body. Acute phase reaction refers to this early response. Inflammation or an inflammatory reaction are other terms for it. Chronic diseases, such as autoimmune diseases, might trigger the acute phase response. According to the National Institutes of Health, an autoimmune disorder affects up to 23.5 million Americans (about 7% of the population), and the number is propelling at a rapid pace. C.R.P. is a pattern recognition molecule that binds to certain chemical combinations seen on pathogen surfaces. C-reactive protein (C.R.P.) has been a significant risk factor for cardiovascular disease. C-reactive protein test mg/dl is the unit of the test. In other words, the C-reactive protein (C.R.P.) is a key protein in the acute phase response. Its blood levels have long been utilized as a non-invasive indicator of any ongoing inflammatory response, including cancer-related inflammation. A c-reactive protein test for cancer is being done by doctors. A C-Reactive Protein Quant test is utilized in the diagnosis of infections or diseases which may cause inflammation. Sometimes it might turn into an autoimmune disease. C-reactive protein levels can be checked with a simple blood test. A high-sensitivity C-reactive protein (HS-CRP) test is more sensitive than a standard C.R.P. test. C.R.P. is a positive acute-phase reactant since it is an early responder. Its level, which is determined by a blood sample, informs doctors about the presence of inflammation and its severity. On the other hand, C.R.P. levels do not inform doctors where the inflammation is in your body or what is generating it. In general, the results of the C.R.P. test are to be expressed in milligrams per deciliter (mg/dL) or milligrams per liter (mg/L). It is expressed as : A typical result: Less than 10 milligrams per liter A high result: Equal to or greater than 10 milligrams per liter The National Library of Medicine undertook a study in 2020 to predict the severity of COVID-19 infection in patients. In comparison to other hematologic and inflammatory indicators, researchers investigated whether the C-reactive protein level (C.R.P.) can serve as a close indicator of disease severity during COVID-19 infection. In the result of the study, researchers found that the C.R.P. level was discovered to be a simple and independent indicator that can be effective for early diagnosis of severity during COVID-19 and easy primary care counseling. Market Dynamics Drivers: Inflammatory disorders, Diabetes, and Cancers According to the University of Rochester Medical Center (URMC), the C-reactive protein (C.R.P.) test is used to determine whether or not the body is inflamed. Inflammation is induced by various factors, including infections and autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. This test implicates what is the level of C.R.P. present in the blood. In the estimation of the National Cancer Institute, in the United States, approximately 1,806,590 cases of cancer were identified in 2020, and approximately 606,520 people died from the disease. Thyroid, testicular, and melanoma skin cancer will be the most commonly diagnosed cancers in ages 20-29 years in 2020, and moreover, breast, thyroid, and melanoma skin cancer will be the most commonly diagnosed cancers in between the ages 30-39 years. According to American Heart Association Statistics 2022, cardiovascular disease (CVD) was reported as the underlying reason for death in the United States, accounting for 874,613 deaths. A myocardial infarction occurs approximately every 40 seconds in the United States, and a stroke victim dies every 3 minutes and 30 seconds on average. These scenarios are driving the growth of the C.R.P. testing market. Due to the growing usage of C.R.P. markers and the increase in the rates of the diseases like Inflammatory bowel disease, Bacterial infections, rheumatoid arthritis, and osteomyelitis, the market for c-reactive protein testing market is expected to increase rapidly. Restraints: Inadequate Test Coverage and Failure to meet the user needs Due to the wide availability of various alternative testing methods for diseases with higher accuracy rates like the echocardiogram (ultrasound), electrocardiogram (E.C.G.) in terms of screening of several cardiac diseases, and various other products for other diseases is anticipated to obstruct the overall growth of the market. Opportunity: Enhanced Healthcare Infrastructure, unmet healthcare demands, and increase in R&D efforts According to a journal published in Frontiers, C.R.P. is not only a good biomarker for chronic inflammation but also plays a vital role in the pathological process. The ability to distinguish between physiological and pathological C.R.P. levels may aid in the treatment of inflammatory illnesses. Due to enhanced healthcare infrastructure, an increase in unmet healthcare demands, and an increase in R&D efforts, new emerging markets are likely to offer substantial growth prospects. Furthermore, significant technological improvements in rapid diagnostic kits are creating a new opportunity for important competitors to enter the c-reactive protein testing market. According to the World Health Organization, around 17.9 million people die annually from cardiovascular diseases worldwide. C.R.P. tests help clinicians detect inflammatory activity within the blood vessels in the case of a heart attack. According to American Heart Association, C.R.P.'s identification as a powerful independent predictor of future cardiovascular risk is backed up by compelling research. C.R.P. predicts cardiovascular risk in both men and women in various clinical scenarios. This strong link to future cardiovascular events has given C.R.P. a new analytic possibility in clinical practice. C-reactive Protein Testing Market Analysis Of Different Segments The global industry is bifurcated into assay type, application, and region. Key Industry Segments By Assay Type: Chemiluminescence Immunoassay (CLIA) Enzyme-linked immunosorbent assay (ELISA) Immunoturbidimetric assays Others By Application: Rheumatoid Arthritis Diabetes Cardiovascular Disease Inflammatory Bowel Disease Others By Region: North America The U.S. Mexico Canada Mexico Europe UK Germany France Spain Italy Rest of Europe Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific LAMEA Brazil South Africa Saudi Arabia Rest of LAMEA Based on the Assay, in 2020, due to the better sensitivity and rapid result technology, the immunoturbidimetric assay segment dominated the C.R.P. testing market, and this trend is likely to continue over the forecasted period. The National Library of Medicine organized a study for the determination of C-reactive protein (C.R.P.) and high-sensitivity C.R.P. (HS-CRP), which are indicators of systemic inflammation and Atherosclerosis risk, normally require using serum samples, whereas heparin plasma samples are taken for routine chemistry. The utility of heparin plasma samples for HS-CRP and C.R.P. measurements utilizing immunoturbidimetric techniques on an Olympus system is evaluated in the study. Based on the Application, in 2020, the cardiovascular disease segment had the largest c-reactive protein testing market share, and this overall trend is likely to continue during the forecasted period. It is primarily due to an increase in cardiovascular diseases on a global basis.. The World Health Organization asserts that cardiovascular diseases are the leading cause of death globally, claiming the lives of an estimated 17.9 million people per year. Based on the Region, in 2020, North America had the bulk of the global industry size, and this trend is expected to continue over the forecast period. This is due to an increase in the prevalence of inflammatory illnesses, an increase in unhealthy lifestyles, the development of novel detection solutions, and an increase in healthcare spending in the region. For example, the Centers for Medical & Medicaid Services claims that in 2020, healthcare spending in the United States will increase by 9.7%, reaching USD 4.1 trillion, or USD 12,530 per person. Health spending accounted for 19.7% of the nation's Gross Domestic Product. Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 2.76 billion The revenue forecast in 2030 USD 3.42 billion Growth rate CAGR of approximately 2.4 % The base year for estimation 2021 Historical data 2015 – 2019 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Assay Type, By Application, By Region By Assay Type Type Chemiluminescence Immunoassay (CLIA), Enzyme-linked immunosorbent assay (ELISA), Immunoturbidimetric assays, Others By Application Type Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Inflammatory Bowel Disease, Others By Region Asia Pacific, North America, Europe, LAMEA Country Scope U.S., Canada, France, Germany, the U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E., etc. Company Usability Profiles Abbott, Zoetis, BODITECH MED, INC., Ortho Clinical Diagnostics, Getein Biotech, Inc., Aidan, HORIBA, Ltd C-reactive Protein Testing Market Competitive Landscape Analysis The key players have growth plans to boost C-reactive protein testing and industry share. In July 2021, Boditech Med, Inc. announced that it would invest approximately $ 6 million in establishing a new Research & Development center in Chuncheon, South Korea. By March 2022, the facility should be up and running. Some of the major key players in the industry include: Siemens Healthineers AG Thermo Fisher Scientific, inc. F. Hoffmann-La Roche Ltd. Danaher Merck KGaAA Quest Diagnostics Abbott Zoetis BOWDITCH MED, I.N.C. Ortho Clinical Diagnostics Getein Biotech, Inc. Aidan HORIBA, Ltd Randox Laboratories Ltd. Recent Developments A study was undertaken by the National Library of Medicine on a newly designed mobile/quick C.R.P. measuring device that used a gold-linked electrochemical immunoassay (GLEIA) method. The objective of this study was to see if this mobile CRP-testing device was feasible. According to the study's findings, this new mobile CRP-testing equipment could be useful in home-based care settings. In January 2022, LumiraDx received C.E. mark clearance for its C-reactive protein PCR test. It's a microfluidic immunoassay test for quantitatively detecting C-reactive protein that's small, portable, and takes only four minutes to complete. In August 2021, Immunovia, Inc. announced that it had gained final approval to commence patient testing for the IMMray PanCan-d test, which is fully dedicated to the early detection of pancreatic cancer on the market. According to the National Library of Medicine, C-reactive protein (C.R.P.) has emerged as a growing market for identifying systemic inflammatory conditions, offering various preliminary information to clinicians for continuing with more specific diagnostic techniques. Enhancements in electroanalytical chemistry and vast knowledge of nanomaterials have assisted modern-age researchers in miniaturizing detection systems with an enhanced level of specificity and sensitivity of C.R.P. detection. Various C-reactive Protein Testing Devices That Key Market Leaders Develop Name of the Product Function Key Player Easy C.R.P. Provides Quantitative C.R.P. test results within 2 minutes Quick read Go C.R.P. Cartridge Used for quantitation of C.R.P. Simple Plex Recombinant Anti-BDNF antibody It produces recombinantly (animal-free) for high batch-to-batch consistency and long-term security of supply. Rabbit CRP ELISA kit It allows the antibody-antigen complex formation in one single step, reducing assay time to 90 minutes. Abcam Frequently Asked Question About This Report How big is the c-reactive protein testing market? The global c-reactive protein testing market size was $2.76 Bn in 2021 and is predicted to reach $3.42 Bn by 2030, with a CAGR of 2.4%. Who are the important key players in the market? Siemens Healthineers AG, Thermo Fisher Scientific, inc., F. Hoffmann-La Roche Ltd., Danaher, Merck KGaAA, Quest Diagnostics, Abbott, Zoetis, BODITECH MED, INC., Ortho Clinical Diagnostics, Getein Biotech, Inc., Aidian, HORIBA, Ltd, Randox Laboratories Ltd., are some of the major key players. What is the c-reactive protein testing market growth? The global c-reactive protein testing market is expected to grow at a compound annual growth rate (CAGR) of 2.4% from 2021 to 2030 to reach USD3.42 billion by 2030. What is CRP market? CRP is an acute-phase protein secreted by the liver, whose blood levels rise in reaction to inflammatory conditions. The level of CRP in the blood plasma is determined by the c-reactive protein (CRP) test. What does the C-reactive protein test detect? The level of c-reactive protein (CRP) which is present in the blood is measured in the c-reactive protein test Is C-reactive protein a good indicator? The C-reactive protein is a better indicator of cardiovascular disease in comparison to the LDL test Is there a home test for C-reactive protein? Yes, there is a home test for C-reactive protein. What is the base year that is considered in the market report? The base year calculated is 2021 in the market report. Which one is the most impactful segment growing in the report? In 2020, the segment of immunoturbidimetric assays dominated the global market. . 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 C-reactive Protein Testing Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global C-reactive Protein Testing Market 4.2.1 Global C-reactive Protein Testing market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Global C-reactive Protein Testing market, by Region, 2021-2030 (USD Million) 4.4 Assay Type Business Analysis 4.4.1 Global C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 4.5 Application Business Analysis 4.5.1 Global C-reactive Protein Testing market, By Application, 2021-2030 (USD Million) 4.6 Value Chain Analysis 4.7 Market Variable Analysis 4.7.1 Market Drivers Analysis 4.7.2 Market Restraints Analysis 4.8 Business Environment Analysis Tool 4.8.1 C-reactive Protein Testing market PEST analysis 4.8.2 C-reactive Protein Testing market Porter’s analysis 4.9 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On C-reactive Protein Testing Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2020) 5.11.2. Trends in Technology (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers C-reactive Protein Testing Manufacturing Sites, Area Served, Assay Type 6.3. C-reactive Protein Testing Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global C-reactive Protein Testing Market: By Assay Type Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Chemiluminescence Immunoassay (CLIA) 7.3.1. Chemiluminescence Immunoassay (CLIA) market, 2021-2030 (USD Million) 7.4. Enzyme-linked immunosorbent assay (ELISA) 7.4.1. Enzyme-linked immunosorbent assay (ELISA) market, 2021-2030 (USD Million) 7.5. Immunoturbidimetric assays 7.5.1. Immunoturbidimetric assays market, 2021-2030 (USD Million) 7.6. Others 7.6.1. Others market, 2021-2030 (USD Million) 8. Global C-reactive Protein Testing Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Rheumatoid Arthritis 8.3.1. Rheumatoid Arthritis market, 2021-2030 (USD Million) 8.4.Diabetes 8.4.1. Diabetes market, 2021-2030 (USD Million) 8.5 Cardiovascular Disease 8.5.1 Cardiovascular Diseasemarket, 2021-2030 (USD Million) 8.5 Inflammatory Bowel Disease 8.5.1 Inflammatory Bowel Disease market, 2021-2030 (USD Million) 8.5 Others 8.5.1 Others market, 2021-2030 (USD Million) 9. Global C-reactive Protein Testing Market: Regional Outlook 9.1 North America 9.1.1. North America C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.1.4. North America C-reactive Protein Testing market, By Application, 2021-2030 (USD Million) 9.1.5. North America C-reactive Protein Testing market, by Country, 2021-2030 (USD Million) 9.1.4.1. U.S. 9.1.4.1.1. U.S. C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.1.4.2. Canada 9.1.4.2.1. Canada C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.1.4.2.2. Canada C-reactive Protein Testing market, By Region, 2021-2030 (USD Million) 9.1.4.2.3. Canada C-reactive Protein Testing market, by Applications, 2021-2030 (USD Million) 9.2. Europe 9.2.1. Europe C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.2.2. Europe C-reactive Protein Testing market, by By Application, 2021-2030 (USD Million) 9.2.5. Europe C-reactive Protein Testing market, by country, 2021-2030 (USD Million) 9.2.4.1 U.K. 9.2.4.1.1. U.K. C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.2.4.1.2. U.K. C-reactive Protein Testing market, By Applications, 2021-2030 (USD Million) 9.2.4.1.3. U.K. C-reactive Protein Testing market, by Region, 2021-2030 (USD Million) 9.2.4.2. Germany 9.2.4.2.1. Germany C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.2.4.2.2. Germany C-reactive Protein Testing market, By Application, 2021-2030 (USD Million) 9.2.4.2.3. Germany C-reactive Protein Testing market, by Region, 2021-2030 (USD Million) 9.2.4.3. France 9.2.4.3.1. France C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.2.4.3.2. France C-reactive Protein Testing market, By Region, 2021-2030 (USD Million) 9.2.4.3.3. France C-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.2.4.4. Rest of Europe 9.2.4.4.1. Rest of Europe C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.2.4.4.2. Rest of Europe C-reactive Protein Testing market, By Region, 2021-2030 (USD Million) 9.2.4.4.3. Rest of Europe C-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.3. Asia Pacific 9.3.1. Asia Pacific C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.3.2. Asia Pacific C-reactive Protein Testing market, By Application, 2021-2030 (USD Million) 9.3.5. Asia Pacific C-reactive Protein Testing market, by country, 2021-2030 (USD Million) 9.3.4.1. China 9.3.4.1.1. China C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.3.4.1.2. China C-reactive Protein Testing market, By Region, 2021-2030 (USD Million) 9.3.4.1.3. China C-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.3.4.2. India 9.3.4.2.1. India C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.3.4.2.2. India C-reactive Protein Testing market, By Region, 2021-2030 (USD Million) 9.3.4.2.3. India C-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.3.4.3. Japan 9.3.4.3.1. JapanC-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.3.4.3.3. Japan C-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.3.4.4. South Korea 9.3.4.4.1. South Korea C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.3.4.4.3. South Korea C-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.3.4.5. Rest of ASIA PACIFIC 9.3.4.5.1. Rest of ASIA PACIFICC-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.3.4.5.3. Rest of ASIA PACIFICC-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.4. Latin America 9.4.1. Latin America C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.4.3. Latin America C-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.4.4. Latin America C-reactive Protein Testing market, by country, 2021-2030 (USD Million) 9.4.4.1. Brazil 9.4.4.1.1. Brazil C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.4.4.1.3. Brazil C-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.4.4.2. Mexico 9.4.4.2.1. Mexico C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.4.4.2.3. Mexico C-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.4.4.3. Rest of the Latin America 9.4.4.3.1. Rest of the Latin AmericaC-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.4.4.3.3. Rest of the Latin AmericaC-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 9.5. MEA 9.5.1. MEA C-reactive Protein Testing market, By Assay Type, 2021-2030 (USD Million) 9.5.3. MEA C-reactive Protein Testing market, by Application, 2021-2030 (USD Million) 10. Competitive Landscape 10.1 Siemens Healthineers AG. 10.1.1. Company overview 10.1.2. Financial performance 10.1.3. ProductPortfolio Analysis 10.1.4. Business Strategy & Recent Development 10.2. Thermo Fisher Scientific, inc. 10.2.1. Company overview 10.2.2. Financial performance 10.2.3. Product Portfolio Analysis 10.2.4. Business Strategy & Recent Development 10.3. F. Hoffmann-La Roche Ltd. 10.3.1. Company overview 10.3.2. Financial performance 10.3.3. Product Portfolio Analysis 10.3.4. Business Strategy & Recent Development 10.4. Danaher. 10.4.1. Company overview 10.4.2. Financial performance 10.4.3. Product Portfolio Analysis 10.4.4. Business Strategy & Recent Development 10.5. Merck KGaAA 10.5.1. Company overview 10.5.2. Financial performance 10.5.3. Product Portfolio Analysis 10.5.4. Business Strategy & Recent Development 10.6. Quest Diagnostics. 10.6.1. Company overview 10.6.2. Financial performance 10.6.3. Product Portfolio Analysis 10.6.4. Business Strategy & Recent Development 10.7. Abbott. 10.7.1. Company overview 10.7.2. Financial performance 10.7.3. Product Portfolio Analysis 10.7.4. Business Strategy & Recent Development 10.8. Zoetis. 10.8.1. Company overview 10.8.2. Financial performance 10.8.3. Product Portfolio Analysis 10.8.4. Business Strategy & Recent Development 10.9. BODITECH MED, INC. 10.9.1. Company overview 10.9.2. Financial performance 10.9.3. Product Portfolio Analysis 10.9.4. Business Strategy & Recent Development 10.10. Ortho Clinical Diagnostics. 10.10.1. Company overview 10.10.2. Financial performance 10.10.3. Product Portfolio Analysis 10.10.4. Business Strategy & Recent Development 10.11. Getein Biotech, Inc. 10.11.1. Company overview 10.11.2. Financial performance 10.11.3. Product Portfolio Analysis 10.11.4. Business Strategy & Recent Development 10.12.Aidian. 10.12.1. Company overview 10.12.2. Financial performance 10.12.3. Product Portfolio Analysis 10.12.4. Business Strategy & Recent Development 10.13. HORIBA, Ltd. 10.13.1. Company overview 10.13.2. Financial performance 10.13.3. Product Portfolio Analysis 10.13.4. Business Strategy & Recent Development 10.14. Randox Laboratories Ltd. 10.14.1. Company overview 10.14.2. Financial performance 10.14.3. Product Portfolio Analysis 10.14.4. Business Strategy & Recent Development List of Tables (65 Tables) TABLE 1. C-reactive Protein Testing MARKET, By Assay Type, 2021-2030 (USD Million) TABLE 2. C-reactive Protein Testing MARKET FOR Chemiluminescence Immunoassay (CLIA), BY REGION, 2021-2030 (USD Million) TABLE 3. C-reactive Protein Testing MARKET FOR Enzyme-linked immunosorbent assay (ELISA), BY REGION, 2021-2030 (USD Million) TABLE 4. C-reactive Protein Testing MARKET FOR Immunoturbidimetric assays, BY REGION, 2021-2030 (USD Million) TABLE 5. C-reactive Protein Testing MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 6. C-reactive Protein Testing MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 7. C-reactive Protein Testing MARKET FOR Rheumatoid Arthritis, BY REGION, 2021-2030 (USD Million) TABLE 8. C-reactive Protein Testing MARKET FOR Diabetes, BY REGION, 2021-2030 (USD Million) TABLE 9. C-reactive Protein Testing MARKET FOR Cardiovascular Disease, BY REGION, 2021-2030 (USD Million) TABLE 10. C-reactive Protein Testing MARKET FOR Inflammatory Bowel Disease, BY REGION, 2021-2030 (USD Million) TABLE 11. C-reactive Protein Testing MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 12. C-reactive Protein Testing MARKET, BY REGION, 2021-2030 (USD Million) TABLE 13. NORTH AMERICA C-reactive Protein Testing MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 14. NORTH AMERICA C-reactive Protein Testing MARKET, BY Applications, 2021-2030 (USD Million) TABLE 15. NORTH AMERICA C-reactive Protein Testing MARKET, By Assay Type, 2021-2030 (USD Million) TABLE 16. NORTH AMERICA C-reactive Protein Testing MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 17. EUROPE C-reactive Protein Testing MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 18. EUROPE C-reactive Protein Testing MARKET, By Assay Type, 2021-2030 (USD Million) TABLE 19. EUROPE C-reactive Protein Testing MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 20. ASIA-PACIFIC C-reactive Protein Testing MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 21. ASIA-PACIFIC C-reactive Protein Testing MARKET, By Assay Type, 2021-2030 (USD Million) TABLE 22. ASIA-PACIFIC C-reactive Protein Testing MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 23. LAMEA C-reactive Protein Testing MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 24. LAMEA C-reactive Protein Testing MARKET, By Assay Type, 2021-2030 (USD Million) TABLE 25. LAMEA C-reactive Protein Testing MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 26. Siemens Healthineers AG: COMPANY SNAPSHOT TABLE 27. Siemens Healthineers AG: OPERATING SEGMENTS TABLE 28. Thermo Fisher Scientific, inc: COMPANY SNAPSHOT TABLE 29. Thermo Fisher Scientific, inc: OPERATING SEGMENTS TABLE 30. F. Hoffmann-La Roche Ltd: COMPANY SNAPSHOT TABLE 31. F. Hoffmann-La Roche Ltd: OPERATING SEGMENTS TABLE 32. Danaher: COMPANY SNAPSHOT TABLE 33. Danaher: OPERATING SEGMENTS TABLE 34. Merck KGaAA: COMPANY SNAPSHOT TABLE 35. Merck KGaAA: OPERATING SEGMENTS TABLE 36. Quest Diagnostics: COMPANY SNAPSHOT TABLE 37. Quest Diagnostics: OPERATING SEGMENTS TABLE 38. Abbott: COMPANY SNAPSHOT TABLE 39. Abbott: OPERATING SEGMENTS TABLE 40. Zoetis: COMPANY SNAPSHOT TABLE 41. Zoetis: OPERATING SEGMENTS TABLE 42. BODITECH MED, INC: COMPANY SNAPSHOT TABLE 43. BODITECH MED, INC: OPERATING SEGMENTS TABLE 44. Ortho Clinical Diagnostics: COMPANY SNAPSHOT TABLE 45. Ortho Clinical Diagnostics: OPERATING SEGMENTS TABLE 46. Getein Biotech, Inc: COMPANY SNAPSHOT TABLE 47. Getein Biotech, Inc: OPERATING SEGMENTS TABLE 48. Aidian.: COMPANY SNAPSHOT TABLE 49. Aidian.: OPERATING SEGMENTS TABLE 50. HORIBA, Ltd: COMPANY SNAPSHOT TABLE 51. HORIBA, Ltd: OPERATING SEGMENTS TABLE 52. Randox Laboratories Ltd: COMPANY SNAPSHOT TABLE 53. Randox Laboratories Ltd: OPERATING SEGMENTS List of Figures (20 Figures) Figure 1 C-reactive Protein Testing Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: C-reactive Protein Testing Market Figure 4 Research Methodology: Hypothesis Building Figure 5 C-reactive Protein Testing Market: Product-Based Estimation Figure 6 Top 14 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for C-reactive Protein Testing, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for C-reactive Protein Testing, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11C-reactive Protein Testing Market, By Applications, 2019 vs. 2025 (USD Million) Figure 12C-reactive Protein Testing Market Share, By Assay Type, 2019 vs. 2025 Figure 13 Geographical Snapshot of the C-reactive Protein Testing Market Figure 14 immunoturbidimetric assay to Witness Higher CAGR in C-reactive Protein Testing Market for Assay TypeSegment during Forecast Period. Figure 15 cardiovascular diseases to Witness Higher CAGR in C-reactive Protein Testing Market for Application Segment during Forecast Period. Figure 16 North America Accounted for the Largest Share of the C-reactive Protein Testing Market, By Regional Basis, in 2019 Figure 17C-reactive Protein Testing Market: Drivers, Restraints, Opportunities, and Challenges Figure 18 North America: C-reactive Protein Testing Market Snapshot Figure 19 Asia Pacific: C-reactive Protein Testing Market Snapshot Figure 20 Vendor Dive: Evaluation Overview